Genomeditech(Shanghai) Co.LTD

EN

Insights

Press Release

Current position：News > Insights

Insights

ASCO 2026: Bispecific Antibodies Enter a New Phase of Immuno-Oncology Competition

From Deals to Discovery Engines: How Big Pharma Is Redefining Early Drug Development

Pharmaceutical R&D is being reshaped by a wave of ecosystem-style partnerships and platform-driven collaborations across the biopharma industry, signaling a clear shift toward earlier, more integrated discovery strategies. At the same time, early functional validation is becoming a critical gatekeeper in preclinical decision-making, especially as new modalities increase the complexity of mechanism-of-action confirmation.

Behind these shifts is a broader redefinition of how confidence is built in drug candidates at the very beginning of development—where speed, biological relevance, and reproducibility increasingly determine downstream success.

LGR5: A Potential Target for Next-Generation Cancer Therapies

Is LGR5 the next key target in cancer therapy?
A new Trends in Cancer review highlights LGR5’s role in tumor plasticity, therapeutic resistance, and its growing potential as a drug target.
From Wnt/β-catenin signaling to emerging strategies like bispecific antibodies and ADCs, LGR5 is moving to the forefront of oncology research—despite ongoing challenges in mechanism and resistance.

GLP-1 Landscape Shift: The Rise of Oral Weight-Loss Therapies

Metabolic disease treatment is entering a new era.

While GLP-1 therapies continue to lead, emerging targets like GIPR, GCGR, FGF21, Amylin, and ActRII are driving the shift toward multi-target strategies. At the same time, oral GLP-1 drugs are intensifying competition between Novo Nordisk and Eli Lilly.

Where is the field heading next? Read the full article for key insights.

TSLP: A Promising Next-Generation Target in Autoimmune Diseases

TSLP is rapidly emerging as one of the most strategically important targets in immunology, driven by its unique role as an upstream regulator of inflammatory pathways. With recent clinical progress, strong commercial validation and a rapidly expanding pipeline are accelerating interest from both global pharma and biotech companies. From monoclonal antibodies to multi-specific formats and long-acting solutions, the diversity of approaches highlights the scale of opportunity ahead.

The IL-17 Pathway Revisited: Mechanistic Maturity and Emerging Opportunities in Immunology

The IL-17 pathway is re-entering the spotlight as new clinical data and mechanistic insights drive the shift from single IL-17A inhibition to dual IL-17A/F targeting.

This article highlights how cytokine redundancy is shaping next-generation therapies, while a mature target continues to evolve across indications and global markets.

Explore how incremental innovation is unlocking new differentiation in one of immunology’s most established pathways.

IL-4 vs. IL-13: Who Will Lead the Next Wave of Autoimmune Therapies?

IL-4 and IL-13 are emerging as central drivers of type 2 inflammation—and the race to target this pathway is accelerating. With blockbuster biologics reshaping the autoimmune therapy market and new approvals continuing to expand their clinical reach, the IL-4/IL-13 axis has quickly become one of the most competitive areas in global immunology R&D. As next-generation approaches begin to emerge, a key question is taking shape across the industry: which pathway will define the next wave of autoimmune therapies?

IL-23: A Rising Target in Autoimmune Disease

TNF-α: Renewed Focus in Autoimmune Disease Therapy

Autoimmune diseases affect millions, and unmet needs remain high. TNF-α inhibitors are a cornerstone of therapy, and innovation continues.

Sorriso Pharmaceuticals’ oral bispecific antibody SOR102 targets TNF-α and IL-23p19 and shows promising safety and early efficacy in ulcerative colitis—offering a more convenient, gut-focused alternative to injectable therapies.

Global efforts in TNF/TNFR-targeted therapies—from receptor-selective drugs to fusion proteins—are redefining treatment possibilities for autoimmune diseases.

PD-1 Agonists: Insights into Their Growing Impact

PD-1 has long been a milestone target in cancer immunotherapy, with PD-1/PD-L1 inhibitors driving major advances in oncology. Now, the same pathway is being explored from the opposite angle: PD-1 agonists for autoimmune diseases. By enhancing immune inhibition, these therapies aim to suppress overactive T cells, addressing conditions such as rheumatoid arthritis, SLE, and primary Sjogren’s syndrome.

First 1 2 3 4 5 Next Last

Total 8 Page

Jump

Current position：News > Insights

classify

Insights

ASCO 2026: Bispecific Antibodies Enter a New Phase of Immuno-Oncology Competition

From Deals to Discovery Engines: How Big Pharma Is Redefining Early Drug Development

Pharmaceutical R&D is being reshaped by a wave of ecosystem-style partnerships and platform-driven collaborations across the biopharma industry, signaling a clear shift toward earlier, more integrated discovery strategies. At the same time, early functional validation is becoming a critical gatekeeper in preclinical decision-making, especially as new modalities increase the complexity of mechanism-of-action confirmation.

Behind these shifts is a broader redefinition of how confidence is built in drug candidates at the very beginning of development—where speed, biological relevance, and reproducibility increasingly determine downstream success.

LGR5: A Potential Target for Next-Generation Cancer Therapies

Is LGR5 the next key target in cancer therapy?
A new Trends in Cancer review highlights LGR5’s role in tumor plasticity, therapeutic resistance, and its growing potential as a drug target.
From Wnt/β-catenin signaling to emerging strategies like bispecific antibodies and ADCs, LGR5 is moving to the forefront of oncology research—despite ongoing challenges in mechanism and resistance.

GLP-1 Landscape Shift: The Rise of Oral Weight-Loss Therapies

Metabolic disease treatment is entering a new era.

While GLP-1 therapies continue to lead, emerging targets like GIPR, GCGR, FGF21, Amylin, and ActRII are driving the shift toward multi-target strategies. At the same time, oral GLP-1 drugs are intensifying competition between Novo Nordisk and Eli Lilly.

Where is the field heading next? Read the full article for key insights.

TSLP: A Promising Next-Generation Target in Autoimmune Diseases

TSLP is rapidly emerging as one of the most strategically important targets in immunology, driven by its unique role as an upstream regulator of inflammatory pathways. With recent clinical progress, strong commercial validation and a rapidly expanding pipeline are accelerating interest from both global pharma and biotech companies. From monoclonal antibodies to multi-specific formats and long-acting solutions, the diversity of approaches highlights the scale of opportunity ahead.

The IL-17 Pathway Revisited: Mechanistic Maturity and Emerging Opportunities in Immunology

The IL-17 pathway is re-entering the spotlight as new clinical data and mechanistic insights drive the shift from single IL-17A inhibition to dual IL-17A/F targeting.

This article highlights how cytokine redundancy is shaping next-generation therapies, while a mature target continues to evolve across indications and global markets.

Explore how incremental innovation is unlocking new differentiation in one of immunology’s most established pathways.

IL-4 vs. IL-13: Who Will Lead the Next Wave of Autoimmune Therapies?

IL-4 and IL-13 are emerging as central drivers of type 2 inflammation—and the race to target this pathway is accelerating. With blockbuster biologics reshaping the autoimmune therapy market and new approvals continuing to expand their clinical reach, the IL-4/IL-13 axis has quickly become one of the most competitive areas in global immunology R&D. As next-generation approaches begin to emerge, a key question is taking shape across the industry: which pathway will define the next wave of autoimmune therapies?

IL-23: A Rising Target in Autoimmune Disease

TNF-α: Renewed Focus in Autoimmune Disease Therapy

Autoimmune diseases affect millions, and unmet needs remain high. TNF-α inhibitors are a cornerstone of therapy, and innovation continues.

Sorriso Pharmaceuticals’ oral bispecific antibody SOR102 targets TNF-α and IL-23p19 and shows promising safety and early efficacy in ulcerative colitis—offering a more convenient, gut-focused alternative to injectable therapies.

Global efforts in TNF/TNFR-targeted therapies—from receptor-selective drugs to fusion proteins—are redefining treatment possibilities for autoimmune diseases.

PD-1 Agonists: Insights into Their Growing Impact

PD-1 has long been a milestone target in cancer immunotherapy, with PD-1/PD-L1 inhibitors driving major advances in oncology. Now, the same pathway is being explored from the opposite angle: PD-1 agonists for autoimmune diseases. By enhancing immune inhibition, these therapies aim to suppress overactive T cells, addressing conditions such as rheumatoid arthritis, SLE, and primary Sjogren’s syndrome.

MORE

Insights

Press Release

Message consultation

                    
Toll-free hotline：400-627-9288
                    
Email address：mkt.genomeditech@gmail.com

Company address：5th Floor, Building 1, Lane 299, Kangwei Road, Pudong New District, Shanghai

Copyright © 2023 吉满生物科技（上海）有限公司 All rights reserved.

Message

Message consultation